The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer

Abstract The present study aimed to evaluate the effect of liver metastases on the efficacy from the combination of PD-1/PD-L1 inhibitor with chemotherapy as first-line treatment in lung cancer using the meta-analysis. A total of 8 randomized controlled trials (RCTs) were included. In patients without liver metastases, PD-1/PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 40% and risk of death by 29% (HR = 0.60; 95%CI,0.55– 0.65 and HR = 0.71;95%CI,0.58–0.90 respectively). In patients with liver metastases, PD-1/PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 31% and risk of death by 21% (HR = 0.69;95%CI,0.58–0.81; and HR = 0.79; 95%CI,0.62–0.80, respectively). The pooled ratios of PFS-HRs and OS- HRs reported in lung cancer patients with liver metastases versus those without liver metastases were 1.11 (95%CI, 0.92–1.34) and 1.03 (95%CI, 0.80–1.35), respectively, suggesting that lung cancer patients with and without liver metastases could obtain comparable efficacy.